| Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors 2007 · Homocysteine-lowering group · Myocardial infarction survivors | 2 mg | 1 mg | 6 years | — |
| B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial 2010 · B vitamins · Patients with recent stroke or transient ischaemic attack within the past 7 months | 2 mg | 500 mcg | 1241 days | 4,089 |
| Treatment with B vitamins and incidence of cancer in patients with previous stroke or transient ischemic attack: results of a randomized placebo-controlled trial 2012 · B vitamins · Patients with recent stroke or transient ischemic attack | 2 mg | 500 mcg | 1241 days | 4,082 |
| Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial 2012 · B-vitamins group · Adults with a stroke or transient ischaemic attack within the previous 7 months; men and women, age not restricted | 2 mg | 500 mcg | 1241 days | 4,040 |
| Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial 2008 · Active treatment · Women aged 40 years or older with a history of cardiovascular disease or at least three cardiovascular risk factors | 2.5 mg | 1 mg | 2665 days | 2,721 |
| Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antioxidant and Folic Acid Cardiovascular Study 2009 · folic acid/B6/B12 group · Women at high risk of cardiovascular disease, with preexisting cardiovascular disease or at least three coronary risk factors; women included in these AMD analyses had no AMD diagnosis at baseline. | 2.5 mg | 1 mg | 2665 days | 2,607 |
| Effect of homocysteine-lowering treatment with folic Acid and B vitamins on risk of type 2 diabetes in women: a randomized, controlled trial 2009 · Active treatment · Women aged 45 years or older at high risk for cardiovascular disease, without diabetes at baseline | 2.5 mg | 1 mg | 2665 days | 2,132 |
| Folic Acid, Vitamin B6, and Vitamin B12 in Combination and Age-Related Cataract in a Randomized Trial of Women 2016 · combination treatment group · Women with preexisting cardiovascular disease or at least three coronary risk factors; ages 40 and older | 2.5 mg | 1 mg | 2665 days | 1,969 |
| B vitamins to enhance treatment response to antidepressants in middle-aged and older adults: results from the B-VITAGE randomised, double-blind, placebo-controlled trial 2014 · vitamins · Community-dwelling adults aged 50 years or over with DSM-IV-TR major depression | 2 mg | 500 mcg | 52 weeks | 77 |
| Homocysteine lowering with folic acid and B vitamins in vascular disease 2006 · active-treatment group · Patients aged 55 years or older with vascular disease or diabetes | 2.5 mg | 1 mg | 5 years | — |
| Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer risk in women: a randomized trial 2008 · combined folic acid/vitamin B6/vitamin B12 treatment · Women aged 40 years or older with a history of cardiovascular disease or at least three coronary risk factors | 2.5 mg | 1 mg | 2666 days | — |
| Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial 2009 · vitamin therapy group · Adults with known cardiovascular disease | 2.5 mg | 1 mg | 5 years | — |
| B-vitamins reduce the long-term risk of depression after stroke: The VITATOPS-DEP trial 2010 · B-vitamins · Stroke survivors; age and sex not specified | 2 mg | 500 mcg | 383 days | — |
| Effect of daily vitamin B-12 and folic acid supplementation on fracture incidence in elderly individuals with an elevated plasma homocysteine concentration: B-PROOF, a randomized controlled trial 2014 · vitamin B-12 plus folic acid group · Adults aged 65 years or older with elevated plasma homocysteine concentrations (12–50 μmol/L) | 400 mcg | 500 mcg | 2 years | — |
| Folic Acid and Vitamin B12 Supplementation and the Risk of Cancer: Long-term Follow-up of the B Vitamins for the Prevention of Osteoporotic Fractures (B-PROOF) Trial 2019 · B vitamins · B-PROOF trial participants; age and specific condition not stated in the abstract | 400 mcg | 500 mcg | 3 years | — |
| Equity in adherence to and effect of prenatal food and micronutrient supplementation on child mortality: results from the MINIMat randomized trial, Bangladesh 2014 · EMMS (early food invitation; multiple micronutrients) · Pregnant women in rural Bangladesh, enrolled before 14 weeks’ gestation | 400 mcg | 2.6 mcg | — | — |
| Equity in adherence to and effect of prenatal food and micronutrient supplementation on child mortality: results from the MINIMat randomized trial, Bangladesh 2014 · UMMS (usual food invitation; multiple micronutrients) · Pregnant women in rural Bangladesh, enrolled before 14 weeks’ gestation | 400 mcg | 2.6 mcg | — | — |
| Modifying effects of maternal Hb concentration on infant birth weight in women receiving prenatal iron-containing supplements: a randomised controlled trial 2016 · MMN group · Pregnant women aged at least 20 years, nulliparous, with Hb concentration ≥100 g/L and enrolled before 20 weeks of gestation | 400 mcg | 2.6 mcg | — | — |
| Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial 2008 · folic acid plus vitamin B12 plus vitamin B6 · Adults undergoing coronary angiography with coronary artery disease or aortic valve stenosis | 800 mcg | 400 mcg | 165 weeks | 772 |
| Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial 2008 · folic acid plus vitamin B12 · Adults undergoing coronary angiography with coronary artery disease or aortic valve stenosis | 800 mcg | 400 mcg | 165 weeks | 772 |
| Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial 2002 · homocysteine-lowering therapy · Patients with coronary artery disease after successful percutaneous coronary intervention; age and sex not specified | 1 mg | 400 mcg | 26 weeks | 272 |
| Impact of weekly iron folic acid supplementation with and without vitamin B12 on anaemic adolescent girls: a randomised clinical trial 2016 · Group B · Anaemic adolescent girls aged 11–18 years | 71.4 mcg | — | 26 weeks | 224 |
| Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer 2018 · Supplemented patients · Adults aged at least 18 years with advanced metastatic or locally advanced unresectable esophagogastric carcinoma | 450 mcg | — | 22 weeks | 41 |
| Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial 2005 · daily oral treatment with folate and mecobalamin · Adults aged 65 years or older with residual hemiplegia at least 1 year after a first ischemic stroke | 5 mg | 1.5 mg | 2 years | — |
| 5-methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients 2008 · group B · Hemodialysis patients with end-stage renal disease; age and sex not reported | 5 mg | — | — | — |
| Effectiveness of homocysteine lowering vitamins in prevention of thrombotic tendency at high altitude area: A randomized field trial 2015 · intervention · Indian soldiers freshly inducted to a high-altitude area | 5 mg | 1 mg | 2 years | — |
| Effect of B vitamins and lowering homocysteine on cognitive impairment in patients with previous stroke or transient ischemic attack: a prespecified secondary analysis of a randomized, placebo-controlled trial and meta-analysis 2013 · B-vitamins · Patients with previous stroke or transient ischemic attack who were cognitively unimpaired at the cognitive assessment | 2 mg | 500 mcg | 1241 days | 1,110 |
| Folate and Vitamin B(12)-Related Biomarkers in Relation to Brain Volumes 2016 · B-vitamin group · Adults aged 65 years or older with mildly elevated plasma homocysteine (12–50 µmol/L) | 400 mcg | 500 mcg | 2 years | 106 |
| DHA status influences effects of B-vitamin supplementation on cognitive ageing: a post-hoc analysis of the B-proof trial 2022 · B-vitamin group · Men and women aged 65 years and older with elevated plasma homocysteine levels (12–50 µmol/L), cognitively healthy | 400 mcg | 500 mcg | 2 years | 94 |
| The association of betaine, homocysteine and related metabolites with cognitive function in Dutch elderly people 2007 · cobalamin plus folic acid group · Dutch elderly people; no diagnosed condition stated | 400 mcg | 1 mg | 24 weeks | — |
| A trial of B vitamins and cognitive function among women at high risk of cardiovascular disease 2008 · B vitamin group · Women aged 65 years or older with cardiovascular disease or at least three coronary risk factors; female health professionals | 2.5 mg | 1 mg | 2411 days | — |
| Results of 2-year vitamin B treatment on cognitive performance: secondary data from an RCT 2014 · B-vitamin group · Adults aged 65 years and older with homocysteine levels of 12–50 µmol/L | 400 mcg | 500 mcg | 2 years | — |
| Effects of 2-year vitamin B12 and folic acid supplementation in hyperhomocysteinemic elderly on arterial stiffness and cardiovascular outcomes within the B-PROOF trial 2015 · B-vitamin supplementation · Adults aged at least 65 years with hyperhomocysteinemia (12–50 μmol/l) | 400 mcg | 500 mcg | 2 years | — |
| Effects of Two-Year Vitamin B(12) and Folic Acid Supplementation on Depressive Symptoms and Quality of Life in Older Adults with Elevated Homocysteine Concentrations: Additional Results from the B-PROOF Study, an RCT 2016 · intervention group · Adults aged 65 years or older from the general population with elevated homocysteine concentrations (12–50 µmol/L) | 400 mcg | 500 mcg | 2 years | — |
| B-vitamins and body composition: integrating observational and experimental evidence from the B-PROOF study 2020 · intervention group · Adults aged 65 years and older with elevated homocysteine levels (12–50 µmol/L) | 400 mcg | 500 mcg | 2 years | — |
| A randomized placebo-controlled trial of using B vitamins to prevent cognitive decline in older mild cognitive impairment patients 2020 · B vitamins supplementation · Adults aged 65 years or older with mild cognitive impairment and serum homocysteine ≥10.0 μmol/L | 400 mcg | 500 mcg | 2 years | — |
| B Vitamin Supplementation Slows Cognitive Decline in Mild Cognitive Impairment Patients with Frontal Lobe Atrophy 2022 · B vitamin supplementation · Mild cognitive impairment outpatients; age and sex not specified | 400 mcg | 500 mcg | 2 years | — |
| Effects of a nutritional supplement on the immune response and cytokine production in free-living Chilean elderly 2004 · special nutritional formula · Healthy adults aged 70 years or older with Mini Mental score ≥22 | 400 mcg | 3.8 mcg | 1 year | 30 |
| Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal 2003 · Multiple micronutrients · Pregnant women in rural Nepal | 400 mcg | 2.6 mcg | — | — |
| Multivitamin supplementation of HIV-positive women during pregnancy reduces hypertension 2005 · Multivitamin plus vitamin A · HIV-positive pregnant Tanzanian women | 800 mcg | 50 mcg | — | — |
| Multivitamin supplementation of HIV-positive women during pregnancy reduces hypertension 2005 · Multivitamin without vitamin A · HIV-positive pregnant Tanzanian women | 800 mcg | 50 mcg | — | — |
| Aged garlic extract with supplement is associated with increase in brown adipose, decrease in white adipose tissue and predict lack of progression in coronary atherosclerosis 2013 · AGE-S · Subjects evaluated for coronary artery calcium; age, sex, and specific condition are not stated | 300 mcg | 100 mcg | 1 year | — |
| Predictors of adherence to micronutrient supplementation before and during pregnancy in Vietnam 2017 · MM (multiple micronutrients) preconception group · Women of reproductive age in Vietnam intending to become pregnant | 400 mcg | 0.371 mcg | 54 weeks | 1,469 |
| Effects of antenatal multiple micronutrient supplementation on children's weight and size at 2 years of age in Nepal: follow-up of a double-blind randomised controlled trial 2008 · intervention group · Pregnant women enrolled at no earlier than 12 weeks’ gestation, with singleton pregnancies and gestation up to 20 completed weeks | 400 mcg | 2.6 mcg | — | 600 |
| Effect of antenatal multiple micronutrient supplementation on anthropometry and blood pressure in mid-childhood in Nepal: follow-up of a double-blind randomised controlled trial 2014 · intervention group (multiple micronutrient supplement) · Pregnant women attending antenatal care in Nepal; no specific age range or deficiency criterion stated | 400 mcg | 2.6 mcg | — | 600 |
| Assessing the adherence and acceptability to iron and folic acid compared with multiple micronutrient supplements during pregnancy: a cluster-randomized noninferiority trial in Cambodia 2025 · MMS-180 · Healthy pregnant individuals aged 18–45 years, in the first 14 weeks of a low-risk singleton pregnancy | 400 mcg | 2.6 mcg | 180 days | 516 |
| Assessing the adherence and acceptability to iron and folic acid compared with multiple micronutrient supplements during pregnancy: a cluster-randomized noninferiority trial in Cambodia 2025 · MMS-90 · Healthy pregnant individuals aged 18–45 years, in the first 14 weeks of a low-risk singleton pregnancy | 400 mcg | 2.6 mcg | 180 days | 515 |
| Oral folic acid and vitamin B-12 supplementation to prevent cognitive decline in community-dwelling older adults with depressive symptoms--the Beyond Ageing Project: a randomized controlled trial 2012 · daily oral folic acid + vitamin B-12 supplementation · Adults aged 60–74 with elevated psychological distress | 400 mcg | 100 mcg | 2 years | 450 |
| Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine study 2009 · vitamin group · Adults aged 21 years or older with advanced chronic kidney disease or end-stage renal disease and high plasma homocysteine | 40 mg | 2 mg | 1128 days | 339 |
| High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial 2009 · B-vitamin group · Men and postmenopausal women aged 40 years or older with fasting total homocysteine ≥8.5 μmol/L and no clinical signs or symptoms of cardiovascular disease | 5 mg | 400 mcg | 1132 days | 254 |
| High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial 2008 · high-dose supplement group · Adults over 50 with mild to moderate probable Alzheimer disease and normal vitamin B12 and folate levels | 5 mg | 1 mg | 548 days | 240 |
| Vitamins B12, B6, and folic acid for onset of depressive symptoms in older men: results from a 2-year placebo-controlled randomized trial 2008 · treatment with vitamins · Men aged 75 years and older, free of clinically significant depression at baseline | 2 mg | 400 mcg | 2 years | 150 |
| Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial 2012 · B-vitamin group · Adults aged 70 years or older with mild cognitive impairment | 800 mcg | 500 mcg | 2 years | 133 |
| Vitamin B12 and Folic Acid Improve Gross Motor and Problem-Solving Skills in Young North Indian Children: A Randomized Placebo-Controlled Trial 2015 · Vitamin B12 & Folic Acid · Children aged 6–30 months from low- to middle-socioeconomic-class families in New Delhi, India | 150 mcg | 1.8 mcg | 26 weeks | 101 |
| Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia 2013 · folate plus B12 · Adults aged 18–68 with schizophrenia, stable on antipsychotic treatment and with persistent symptoms | 2 mg | — | 16 weeks | 94 |
| Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial 2010 · Active treatment group · Adults aged 70 years or older with mild cognitive impairment | 800 mcg | 500 mcg | 2 years | 85 |
| Effects of Folic Acid and Vitamin B12 Supplementation on Cognitive Impairment and Inflammation in Patients with Alzheimer's Disease: A Randomized, Single-Blinded, Placebo-Controlled Trial 2021 · Folate and vitB12 group · Adults older than 45 years with probable Alzheimer's disease, MoCA score below 22, receiving dementia medication | 1.2 mg | — | 26 weeks | 60 |
| Improved vascular endothelial function after oral B vitamins: An effect mediated through reduced concentrations of free plasma homocysteine 2000 · Folic acid and vitamin B(12) · Men aged 39–67 years with coronary heart disease | 5 mg | 1 mg | 8 weeks | 59 |
| Additive effect of homocysteine- and cholesterol-lowering therapy on endothelium-dependent vasodilation in patients with cardiovascular disease 2012 · combined therapy · Patients with cardiovascular disease at high cardiovascular risk; age and sex not reported | 1 mg | 400 mcg | 6 weeks | 36 |
| Folate and vitamin B12 supplementation in patients with schizophrenia and low serum folate level: A 24-week randomized, double-blind, placebo-controlled study 2026 · folate group · Patients with schizophrenia and serum folate levels lower than 6 mg/L | 5 mg | 500 mcg | 24 weeks | 36 |
| Additive effect of homocysteine- and cholesterol-lowering therapy on endothelium-dependent vasodilation in patients with cardiovascular disease 2012 · group V · Patients with cardiovascular disease at high cardiovascular risk; age and sex not reported | 1 mg | 400 mcg | 6 weeks | 18 |
| Significant correlations of plasma homocysteine and serum methylmalonic acid with movement and cognitive performance in elderly subjects but no improvement from short-term vitamin therapy: a placebo-controlled randomized study 2005 · Vitamin therapy · Community-dwelling elderly adults, median age 76 years; both sexes; vitamin deficiencies were present in a subset | 800 mcg | 500 mcg | 120 days | — |
| Clinical trial: B vitamins improve health in patients with coeliac disease living on a gluten-free diet 2009 · B vitamin supplementation · Adults aged 45–64 years with longstanding coeliac disease, on a strict gluten-free diet for several years | 800 mcg | 500 mcg | 26 weeks | — |
| A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people 2011 · supplement group · Older people with mild to moderate Alzheimer disease or vascular dementia | 5 mg | 1 mg | 2 years | — |
| Coronary blood flow in patients with stable coronary artery disease treated long term with folic acid and vitamin B12 2011 · Folic acid and vitamin B12, without vitamin B6 · Adults with stable coronary artery disease; mean age 57.8 years; sex not specified | 800 mcg | 400 mcg | 2 years | — |
| Coronary blood flow in patients with stable coronary artery disease treated long term with folic acid and vitamin B12 2011 · Folic acid and vitamin B12 plus vitamin B6 · Adults with stable coronary artery disease; mean age 57.8 years; sex not specified | 800 mcg | 400 mcg | 2 years | — |
| B-Vitamin Therapy for Kidney Transplant Recipients Lowers Homocysteine and Improves Selective Cognitive Outcomes in the Randomized FAVORIT Ancillary Cognitive Trial 2017 · treatment group (high-dose vitamin group) · Men and women aged 35–75 with stable kidney function for at least 6 months after kidney transplantation and elevated plasma homocysteine | 5 mg | 1 mg | 2008 days | — |
| The Vitamins in Psychosis Study: A Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Vitamins B(12), B(6), and Folic Acid on Symptoms and Neurocognition in First-Episode Psychosis 2019 · B-vitamin supplement group · Patients with first-episode psychosis; age and sex not specified | 5 mg | 400 mcg | 12 weeks | — |
| A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) 2000 · combination group · Patients with primary hypercholesterolaemia; age and sex not reported | 2 mg | 800 mcg | 6 weeks | — |
| Associations of maternal nutrition during pregnancy and post-partum with maternal cognition and caregiving 2018 · MMN · Pregnant women enrolled at ≤20 weeks’ gestation in Malawi, followed through 6 months postpartum | 400 mcg | 5.2 mg | 1 year | 239 |
| Associations of maternal nutrition during pregnancy and post-partum with maternal cognition and caregiving 2018 · LNS · Pregnant women enrolled at ≤20 weeks’ gestation in Malawi, followed through 6 months postpartum | 400 mcg | 5.2 mg | 1 year | 234 |
| Enhanced physical and cognitive performance in active duty Airmen: evidence from a randomized multimodal physical fitness and nutritional intervention 2020 · exercise plus nutritional supplement group · Active-duty Air Force Airmen aged 18–45; no qualifying disease or deficiency was stated | 200 mcg | 4 mcg | 12 weeks | 70 |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · NF group, 3-month blinded trial · Community-dwelling adults aged 18–86 years, both sexes, without dementia or clinical memory difficulties | 400 mcg | 6 mcg | 90 days | 59 |
| Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients 2007 · mecobalamin (B12) + multivitamin supplement · Taiwanese men and women aged over 50 with mild to moderate Alzheimer's disease and normal folic acid and vitamin B12 concentrations | 1 mg | 500 mg | 26 weeks | 45 |
| L-Arginine and B vitamins improve endothelial function in subjects with mild to moderate blood pressure elevation 2018 · Nutritional intervention group · Men and postmenopausal women aged 40–65 with slightly to moderately elevated blood pressure | 400 mcg | 2 mcg | 26 weeks | 40 |
| L-Arginine and B vitamins improve endothelial function in subjects with mild to moderate blood pressure elevation 2018 · Placebo group receiving open-label TAP in follow-up · Men and postmenopausal women aged 40–65 with slightly to moderately elevated blood pressure | 400 mcg | 2 mcg | 13 weeks | 40 |
| Effects of Low-Dose Dairy Protein Plus Micronutrient Supplementation during Resistance Exercise on Muscle Mass and Physical Performance in Older Adults: A Randomized, Controlled Trial 2018 · ExPM (resistance exercise plus low-dose dairy protein and micronutrient supplementation) · Adults aged 65–80 years, non-disabled and not exercising regularly | 200 mcg | 12 mcg | 12 weeks | 40 |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · Open-label NF group, separate 6-month trial · Community-dwelling adults, both sexes, without dementia or clinical memory difficulties | 400 mcg | 6 mcg | 26 weeks | 38 |
| Effects of ingesting a pre-workout dietary supplement with and without synephrine for 8 weeks on training adaptations in resistance-trained males 2017 · PWS · Apparently healthy, resistance-trained males; mean age about 21 years | 50 mg | 70 mg | 8 weeks | 27 |
| Effects of ingesting a pre-workout dietary supplement with and without synephrine for 8 weeks on training adaptations in resistance-trained males 2017 · PWS + S · Apparently healthy, resistance-trained males; mean age about 22 years | 50 mg | 70 mg | 8 weeks | 26 |
| Effects of acute ingestion of a pre-workout dietary supplement with and without p-synephrine on resting energy expenditure, cognitive function and exercise performance 2017 · PWS · Resistance-trained healthy adults; 20 men and 5 women, mean age 21.7 years | 50 mg | 70 mg | 1 day | 25 |
| Effects of acute ingestion of a pre-workout dietary supplement with and without p-synephrine on resting energy expenditure, cognitive function and exercise performance 2017 · PWS + S · Resistance-trained healthy adults; 20 men and 5 women, mean age 21.7 years | 50 mg | 70 mg | 1 day | 25 |
| Effects of an L-arginine-based multi ingredient product on endothelial function in subjects with mild to moderate hypertension and hyperhomocysteinemia - a randomized, double-blind, placebo-controlled, cross-over trial 2017 · AbMIP (vasoLoges® protect) · Men and postmenopausal women aged 40–65 with elevated systolic blood pressure and homocysteine ≥10 μmol/L | 600 mcg | 500 mcg | 4 weeks | 25 |
| Short-Term Effects of a Ready-to-Drink Pre-Workout Beverage on Exercise Performance and Recovery 2017 · RTD · Recreationally active men and women aged 18–40 years with at least six months of resistance-training experience | 325 mcg | 45 mcg | 7 days | 25 |
| Opicapone in Parkinson's Disease on Levodopa-Carbidopa Intestinal Gel Treatment: A Pilot, Randomized Study 2025 · addOPC group · Adults with Parkinson's disease receiving levodopa-carbidopa intestinal gel and experiencing nocturnal, morning, or afternoon akinesia | 400 mcg | 5 mcg | 1 year | 11 |
| Opicapone in Parkinson's Disease on Levodopa-Carbidopa Intestinal Gel Treatment: A Pilot, Randomized Study 2025 · nOPC group · Adults with Parkinson's disease receiving levodopa-carbidopa intestinal gel and experiencing nocturnal, morning, or afternoon akinesia | 400 mcg | 5 mcg | 1 year | 11 |
| Micronutrient supplementation may reduce symptoms of depression in Guatemalan women 2009 · weekly 5,000 microg folic acid group · Women in Guatemala; age range and health condition not specified | 714 mcg | — | 12 weeks | — |
| Micronutrient supplementation may reduce symptoms of depression in Guatemalan women 2009 · weekly 2,800 microg folic acid group · Women in Guatemala; age range and health condition not specified | 400 mcg | — | 12 weeks | — |
| Micronutrient supplementation may reduce symptoms of depression in Guatemalan women 2009 · daily 400 microg folic acid group · Women in Guatemala; age range and health condition not specified | 400 mcg | — | 12 weeks | — |
| Micronutrient supplementation may reduce symptoms of depression in Guatemalan women 2009 · daily 200 microg folic acid group · Women in Guatemala; age range and health condition not specified | 200 mcg | — | 12 weeks | — |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · NF group, 2-week blinded trial · Community-dwelling adults, both sexes, without dementia or clinical memory difficulties | 400 mcg | 6 mcg | 2 weeks | — |
| Improving neuropathy scores in type 2 diabetic patients using micronutrients supplementation 2011 · Group MVB · Patients with type 2 diabetes | 1 mg | 10 mcg | 120 days | — |
| Three-month B vitamin supplementation in pre-school children affects folate status and homocysteine, but not cognitive performance 2014 · B vitamin supplementation group · Healthy preschool children selected for low urinary folate-status ranking | 220 mcg | 1.2 mcg | 90 days | — |
| Low-dose B vitamins supplementation ameliorates cardiovascular risk: a double-blind randomized controlled trial in healthy Chinese elderly 2015 · treatment group · Healthy adults aged 60–74 years | 400 mcg | 10 mcg | 1 year | — |
| Folic acid and vitamin B12 supplementation in subjects with type 2 diabetes mellitus: A multi-arm randomized controlled clinical trial 2020 · Group C · Patients with type 2 diabetes mellitus on stable oral antidiabetic drugs | 5 mg | 500 mcg | 8 weeks | 20 |
| Lowering homocysteine with B vitamins has no effect on blood pressure in older adults 2007 · Vitamins group · Healthy adults aged 65 years or older with homocysteine concentrations of at least 13 micromol/L | 1 mg | 500 mcg | 2 years | — |
| A 2-Year Randomized Controlled Trial With Low-Dose B-Vitamin Supplementation Shows Benefits on Bone Mineral Density in Adults With Lower B12 Status 2022 · B-vitamin treatment · Community-dwelling adults aged 50 years or older; men and women; no specific diagnosed condition, and not currently taking B-vitamin supplements at screening | 200 mcg | 10 mcg | 2 years | 103 |
| Aged garlic extract supplemented with B vitamins, folic acid and L-arginine retards the progression of subclinical atherosclerosis: a randomized clinical trial 2009 · AGE+S · Intermediate-risk adults, mean age 60 ± 9 years; 79% male | 300 mcg | 100 mcg | 1 year | — |
| Folic acid and vitamin B(12) supplementation lowers plasma homocysteine but has no effect on serum bone turnover markers in elderly women: a randomized, double-blind, placebo-controlled trial 2013 · vitamin group · Women aged 65–93 years with homocysteine levels greater than 10 μmol/L | 800 mcg | 1 mg | 120 days | 17 |
| Effect of Combined Treatment With Folic Acid, Vitamin B(6), and Vitamin B(12) on Plasma Biomarkers of Inflammation and Endothelial Dysfunction in Women 2018 · Folic Acid/B6/B12 · Adult women at increased cardiovascular risk, with pre-existing cardiovascular disease or at least three coronary risk factors | 2.5 mg | 1 mg | 2665 days | 150 |
| Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease 1998 · Cereal providing 499 microg of folic acid daily · Men and women with coronary artery disease | 499 mcg | — | — | — |
| Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease 1998 · Cereal providing 665 microg of folic acid daily · Men and women with coronary artery disease | 665 mcg | — | — | — |
| Impact of Preconception Micronutrient Supplementation on Anemia and Iron Status during Pregnancy and Postpartum: A Randomized Controlled Trial in Rural Vietnam 2016 · Multiple micronutrients (MM) · Women aged 18–40 planning pregnancy in rural Vietnam; no specific diagnosed condition required | 400 mcg | 0.371 mcg | 56 weeks | 508 |
| A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) 2000 · vitamins alone group · Patients with primary hypercholesterolaemia; age and sex not reported | 2 mg | 800 mcg | 6 weeks | — |
| Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized substudy of the VITATOPS trial 2005 · vitamin therapy · Patients with recent transient ischemic attack or stroke; age and sex not reported | 2 mg | 500 mcg | 26 weeks | — |
| Sustained homocysteine-lowering effect over time of folic acid-based multivitamin therapy in stroke patients despite increasing folate status in the population 2005 · active VITATOPS medication · Patients with stroke or transient ischemic attack | 2 mg | 500 mcg | 26 weeks | — |
| Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, Vitamins B6 and B12 2005 · treatment group · Adults aged 60 ± 8 years with carotid intima-media thickness ≥1 mm and at risk of cerebral ischemia | 2.5 mg | 500 mcg | 1 year | — |
| Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease 2005 · folic acid plus vitamin B-12 · Adults aged 65 years or older with ischemic vascular disease | 2.5 mg | 500 mcg | 1 year | — |
| Effect of long-term homocysteine reduction with B vitamins on arterial wall inflammation assessed by fluorodeoxyglucose positron emission tomography: a randomised double-blind, placebo-controlled trial 2009 · B-vitamin therapy · Adults with a history of ischemic stroke | 2 mg | 500 mcg | 1461 days | — |
| Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial 2010 · B-vitamin group · People with type 1 or type 2 diabetes and a clinical diagnosis of diabetic nephropathy | 2.5 mg | 1 mg | 3 years | — |
| Bread cofortified with folic acid and vitamin B-12 improves the folate and vitamin B-12 status of healthy older people: a randomized controlled trial 2008 · bread fortified with folic acid and vitamin B-12 · Men and women aged 50–75 years described as healthy older people | 138 mcg | 9.6 mcg | 12 weeks | 72 |
| Folic acid causes higher prevalence of detectable unmetabolized folic acid in serum than B-complex: a randomized trial 2016 · B-complex · Elderly people | 400 mcg | 10 mcg | 23 days | 27 |
| Distribution of plasma folate forms in hemodialysis patients receiving high daily doses of L-folinic or folic acid 2002 · Folic acid group · Adults with chronic stable hemodialysis and hyperhomocysteinemia | 15 mg | 1 mg | 12 weeks | 24 |
| Holo-transcobalamin is an early marker of changes in cobalamin homeostasis. A randomized placebo-controlled study 2002 · Vitamin B(12), folic acid, and vitamin B(6) · Patients aged 38–80 years undergoing coronary angiography | 800 mcg | 400 mcg | 12 weeks | — |
| Holo-transcobalamin is an early marker of changes in cobalamin homeostasis. A randomized placebo-controlled study 2002 · Vitamin B(12) and folic acid · Patients aged 38–80 years undergoing coronary angiography | 800 mcg | 400 mcg | 12 weeks | — |
| Plasma vitamin B6 vitamers before and after oral vitamin B6 treatment: a randomized placebo-controlled study 2003 · Group A · Patients aged 38–80 years undergoing coronary angiography | 800 mcg | 400 mcg | 12 weeks | — |
| A randomised double-blind study comparing sodium feredetate with ferrous fumarate in anaemia in pregnancy 2007 · Group A · Pregnant women at 12–26 weeks’ gestation with iron-deficiency anaemia | 3 mg | 30 mcg | 75 days | — |
| A randomised double-blind study comparing sodium feredetate with ferrous fumarate in anaemia in pregnancy 2007 · Group B · Pregnant women at 12–26 weeks’ gestation with iron-deficiency anaemia | 3 mg | 30 mcg | 75 days | — |
| A randomised double-blind study comparing sodium feredetate with ferrous fumarate in anaemia in pregnancy 2007 · Group C · Pregnant women at 12–26 weeks’ gestation with iron-deficiency anaemia | 3 mg | 30 mcg | 75 days | — |
| Vitamin B12 supplementation during pregnancy and postpartum improves B12 status of both mothers and infants but vaccine response in mothers only: a randomized clinical trial in Bangladesh 2016 · B12 supplementation · Bangladeshi pregnant women aged 18–35 years, 11–14 weeks pregnant, with hemoglobin <110 g/L | 400 mcg | 250 mcg | — | — |
| Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease 1998 · Cereal providing 127 microg of folic acid daily · Men and women with coronary artery disease | 127 mcg | — | — | — |
| One year B-vitamins increases serum and whole blood folate forms and lowers plasma homocysteine in older Germans 2015 · B-vitamin supplementation · Older German adults, mean age 67 years | 500 mcg | 500 mcg | 1 year | — |
| Maternal B-vitamin and vitamin D status before, during, and after pregnancy and the influence of supplementation preconception and during pregnancy: Prespecified secondary analysis of the NiPPeR double-blind randomized controlled trial 2023 · intervention · Women planning pregnancy; generally healthy, recruited before conception | 400 mcg | 5.2 mcg | — | 870 |
| Antenatal Multiple Micronutrient Supplementation Compared to Iron-Folic Acid Affects Micronutrient Status but Does Not Eliminate Deficiencies in a Randomized Controlled Trial Among Pregnant Women of Rural Bangladesh 2019 · MM · Pregnant women aged 12–45 years in rural Bangladesh | 600 mcg | 2.6 mcg | 165 days | 749 |
| Daily Folic Acid and/or Vitamin B12 Supplementation Between 6 and 30 Months of Age and Cardiometabolic Risk Markers After 6-7 Years: A Follow-Up of a Randomized Controlled Trial 2023 · Vitamin B12 and folic acid · Children aged 6–30 months at enrollment | 150 mcg | 1.8 mcg | 180 days | 184 |
| Newborn micronutrient status biomarkers in a cluster-randomized trial of antenatal multiple micronutrient compared with iron folic acid supplementation in rural Bangladesh 2020 · MM · Pregnant women in rural Bangladesh; age range not specified; no disease condition specified | 600 mcg | 2.6 mcg | — | 176 |
| Daily supplementation of a multiple micronutrient powder improves folate but not thiamine, riboflavin, or vitamin B(12) status among young Laotian children: a randomized controlled trial 2022 · micronutrient powder group (MNP) · Children aged 6–23 months in rural Lao PDR; no disease-based selection, with high prevalence of undernutrition and micronutrient deficiencies | 150 mcg | 0.9 mcg | 36 weeks | 130 |
| Lowering plasma homocysteine concentrations of older men and women with folate, vitamin B-12, and vitamin B-6 does not affect the proportion of (n-3) long chain polyunsaturated fatty acids in plasma phosphatidylcholine 2008 · vitamin group · Men and women aged 65 years or older with plasma homocysteine concentrations of at least 13 micromol/L | 1 mg | 500 mcg | 2 years | 127 |
| Influence of folic acid and vitamin B12 supplementation on arsenic methylation: A double-blinded, placebo-controlled trial in Bangladeshi children 2024 · FA + B12 supplementation group · Children aged 8–11 years in Bangladesh exposed to drinking-water arsenic above 50 μg/L | 400 mcg | 5 mcg | 12 weeks | 118 |
| Multiple micronutrient supplementation improves vitamin B₁₂ and folate concentrations of HIV infected children in Uganda: a randomized controlled trial 2011 · Multiple micronutrient supplementation (MMS) · HIV-infected children aged 1–5 years | 40 mcg | 2.4 mcg | 26 weeks | 104 |
| Paraoxonase 1, B Vitamins Supplementation, and Mild Cognitive Impairment 2021 · B-vitamin group · Men and women, mean age 77.6 years, with mild cognitive impairment | 800 mcg | 500 mcg | 2 years | 95 |
| Brain atrophy in cognitively impaired elderly: the importance of long-chain ω-3 fatty acids and B vitamin status in a randomized controlled trial 2015 · high-dose B vitamin supplementation · Adults aged 70 years or older with mild cognitive impairment | 800 mcg | 500 mcg | 2 years | 85 |
| The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis 2008 · Vitamins · People with a history of stroke or transient ischemic attack; age range and sex not restricted | 2 mg | — | 4 years | 83 |
| Vitamin B12 decreases, but does not normalize, homocysteine and methylmalonic acid in end-stage renal disease: a link with glycine metabolism and possible explanation of hyperhomocysteinemia in end-stage renal disease 2003 · Daily multivitamin therapy with added vitamin B12 · Adults with end-stage renal disease receiving hemodialysis and with hyperhomocysteinemia | 1 mg | 1 mg | 4 weeks | 81 |
| Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial 2019 · immediate arm (IA) · Adults with locally advanced or metastatic nonsquamous non-small cell lung cancer receiving pemetrexed-based chemotherapy | 1 mg | — | 18 weeks | 81 |
| Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial 2019 · delayed arm (DA) · Adults with locally advanced or metastatic nonsquamous non-small cell lung cancer receiving pemetrexed-based chemotherapy | 1 mg | — | 18 weeks | 80 |
| Hyperhomocysteinemia in Japanese patients with convalescent stage ischemic stroke: effect of combined therapy with folic acid and mecobalamine 2002 · combined vitamin B(12) and folic acid group · Japanese patients with ischemic stroke in the convalescent stage | 5 mg | 1.5 mg | 8 weeks | 64 |
| Weekly iron folate supplementation in adolescent girls--an effective nutritional measure for the management of iron deficiency anaemia 2013 · Daily IFA Supplementation Group · Adolescent girls aged 10–19 years with anaemia (haemoglobin <12 g/dL) | 1.5 mg | 15 mcg | 90 days | 60 |
| Weekly iron as a safe alternative to daily supplementation for nonanemic pregnant women 2006 · Daily supplementation (DS) · Pregnant women with singleton pregnancies, at gestational week 20, with hemoglobin >115 g/L; nonanemic | 200 mcg | 1 mcg | 16 weeks | 56 |
| Homocysteine thiolactone contributes to the prognostic value of fibrin clot structure/function in coronary artery disease 2022 · Folic acid + vitamins B12, B6 · Adults with suspected coronary artery disease undergoing angiography for stable angina; mean age 61.2 years, 71.5% male | 800 mcg | 400 mcg | 1387 days | 52 |
| Homocysteine thiolactone contributes to the prognostic value of fibrin clot structure/function in coronary artery disease 2022 · Folic acid + vitamin B12 · Adults with suspected coronary artery disease undergoing angiography for stable angina; mean age 61.2 years, 71.5% male | 800 mcg | 400 mcg | 1387 days | 52 |
| [Impact of adding folic acid, vitamin B(12) and probucol to standard antihypertensive medication on plasma homocysteine and asymmetric dimethylarginine levels of essential hypertension patients] 2012 · group 2 · Patients with essential hypertension; age and sex not reported | 5 mg | 1 mg | 12 weeks | 40 |
| [Impact of adding folic acid, vitamin B(12) and probucol to standard antihypertensive medication on plasma homocysteine and asymmetric dimethylarginine levels of essential hypertension patients] 2012 · group 3 · Patients with essential hypertension; age and sex not reported | 5 mg | 1 mg | 12 weeks | 40 |
| [Efficacy and safety of two vitamin supplement regimens on homocysteine levels in hemodialysis patients. Prospective, randomized clinical trial] 2005 · Supraphysiological daily-dose regimen · Adults with stable maintenance hemodialysis (mean age 68 years; 48% male) | 15 mg | 1 mg | 1 year | 33 |
| A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours 2006 · Pemetrexed dose-escalation cohorts receiving folate and vitamin B12 supplementation · Japanese adults aged 20–75 with incurable solid tumours | 500 mcg | — | — | 31 |
| Folate, vitamin B12, homocysteine status and DNA damage in young Australian adults 1998 · supplemented group · Young Australian adults aged 18–32 years; males and females; not folate deficient, with 4.4% vitamin B12 deficient | 700 mcg | 7 mcg | 26 weeks | 31 |
| [Effects of intervention therapy of methylcobalamin and folic acid on plasma homocysteine concentration and homocysteine thiolactonases/paraoxonase activity in patients with type 2 diabetes mellitus] 2007 · Group IV · Patients with type 2 diabetes mellitus | 5 mg | — | 12 weeks | 30 |
| Effects of plasma homocysteine levels on serum HTase/PON activity in patients with type 2 diabetes 2008 · Group III · Patients with type 2 diabetes; age and sex not specified | 5 mg | — | 2 weeks | 30 |
| A Randomized Pilot Trial to Evaluate the Bioavailability of Natural versus Synthetic Vitamin B Complexes in Healthy Humans and Their Effects on Homocysteine, Oxidative Stress, and Antioxidant Levels 2019 · Natural vitamin B complex (group N) · Healthy adults; age range and sex not specified | 690 mcg | 8.85 mcg | 6 weeks | 30 |
| A Randomized Pilot Trial to Evaluate the Bioavailability of Natural versus Synthetic Vitamin B Complexes in Healthy Humans and Their Effects on Homocysteine, Oxidative Stress, and Antioxidant Levels 2019 · Synthetic vitamin B complex (group S) · Healthy adults; age range and sex not specified | 690 mcg | 8.85 mcg | 6 weeks | 30 |
| Plasma homocysteine and markers for oxidative stress and inflammation in patients with coronary artery disease--a prospective randomized study of vitamin supplementation 2005 · open therapy with vitamins · Adults with ischemic heart disease and plasma homocysteine at least 15.0 micromol/L | 5 mg | 1 mg | 90 days | 29 |
| Preliminary results of the effect of treatment of hyperhomocysteinemia and its relationship with inflammation, coagulation status, and endothelial function after renal transplantation 2005 · Hyperhomocysteinemia patients treated with folic acid and vitamin B12 · Renal transplant recipients with hyperhomocysteinemia | 10 mg | 500 mg | 90 days | 29 |
| The impact of folate status and folic acid supplementation on the micronucleus frequency in human erythrocytes 2006 · folic acid, vitamin B12 and vitamin B6 supplementation group · Both-sex participants without folate deficiency; age not reported | 800 mcg | 20 mcg | 7 days | 29 |
| Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients 2003 · group A · Adults with hyperhomocysteinemia who were stable renal-transplant recipients | 5 mg | 400 mcg | 26 weeks | 28 |
| [Efficacy and safety of two vitamin supplement regimens on homocysteine levels in hemodialysis patients. Prospective, randomized clinical trial] 2005 · Daily renal multivitamin regimen · Adults with stable maintenance hemodialysis (mean age 68 years; 48% male) | 5 mg | 400 mcg | 1 year | 27 |
| Comparative study of response to treatment with supraphysiologic doses of B-vitamins in hyperhomocysteinemic hemodialysis patients 2004 · Group A · Hemodialysis patients with hyperhomocysteinemia; age and sex not reported | 15 mg | — | — | 26 |
| Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients 2000 · FA group · Adults with chronic, stable hyperhomocysteinemia receiving hemodialysis | 15 mg | 1 mg | 12 weeks | 25 |
| Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients 2001 · Folic acid group · Adults with chronic, stable hyperhomocysteinemia receiving maintenance hemodialysis | 15 mg | 1 mg | 12 weeks | 25 |
| Rapid communication: L-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients 2001 · Folic acid group · Adults with chronic, stable hyperhomocysteinemia receiving hemodialysis | 15 mg | 1 mg | 12 weeks | 24 |
| Comparative study of response to treatment with supraphysiologic doses of B-vitamins in hyperhomocysteinemic hemodialysis patients 2004 · Group B · Hemodialysis patients with hyperhomocysteinemia; age and sex not reported | 15 mg | — | — | 24 |
| Antioxidant supplementation with or without B-group vitamins after acute ischemic stroke: a randomized controlled trial 2006 · B-group vitamins · Acute ischemic stroke patients treated within 12 hours of symptom onset | 5 mg | 400 mcg | 2 weeks | 24 |
| Antioxidant supplementation with or without B-group vitamins after acute ischemic stroke: a randomized controlled trial 2006 · Antioxidant vitamins plus B-group vitamins · Acute ischemic stroke patients treated within 12 hours of symptom onset | 5 mg | 400 mcg | 2 weeks | 24 |
| Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients 1999 · group 1 · Chronic, stable renal transplant recipients; age and sex not stated | 2.4 mg | 400 mcg | 12 weeks | 20 |
| Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients 1999 · group 2 · Chronic, stable renal transplant recipients; age and sex not stated | 400 mcg | 400 mcg | 12 weeks | 20 |
| Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis 2010 · methylcobalamin group · Patients undergoing long-term hemodialysis | 15 mg | — | 3 weeks | 20 |
| Hyperhomocysteinemia and endothelial function in young subjects: effects of vitamin supplementation 2002 · vitamin supplementation · Male volunteers aged 40 years or younger; nine matched pairs received vitamins, including hyperhomocysteinemic and normohomocysteinemic subjects | 600 mcg | 800 mcg | 8 weeks | 18 |
| [Treatment of hyperhomocysteinemia and endothelial dysfunction in renal-transplant recipients with vitamin B] 2005 · vitamin treatment (group A) · Stable hyperhomocysteinemic renal-transplant recipients | 5 mg | 1 mg | 26 weeks | 18 |
| Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial 2020 · DHA treatment arm · Cognitively unimpaired men and women aged 55 years and older with a first-degree family history of dementia | 800 mcg | 1 mg | 26 weeks | 18 |
| Nutritional status-dependent DNA methylation modifications on adipose tissue in systemic lupus erythematosus women following folic acid and vitamin B12 supplementation: a randomized double-blind placebo-controlled trial 2026 · excess-body-weight intervention group · Women aged 18–45 with inactive systemic lupus erythematosus and excess body weight (BMI ≥25 kg/m²) | 400 mcg | 2 mcg | 12 weeks | 14 |
| Nutritional status-dependent DNA methylation modifications on adipose tissue in systemic lupus erythematosus women following folic acid and vitamin B12 supplementation: a randomized double-blind placebo-controlled trial 2026 · normal-weight intervention group · Women aged 18–45 with inactive systemic lupus erythematosus and normal weight (BMI 18.5–24.9 kg/m²) | 400 mcg | 2 mcg | 12 weeks | 11 |
| Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients 2001 · Renal transplant recipients · Renal transplant recipients with hyperhomocysteinemia | 2.4 mg | 400 mcg | 12 weeks | 10 |
| Folic acid and vitamin B12 are more effective than vitamin B6 in lowering fasting plasma homocysteine concentration in patients with coronary artery disease 2004 · folic acid combined with vitamin B(12) · Patients with coronary artery disease and at least 70% stenosis of one major coronary artery | 5 mg | 250 mcg | 12 weeks | 9 |
| Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation 2002 · group II · Haemodialysis patients with chronic renal failure and hyperhomocysteinaemia | 15 mg | — | 3 weeks | 7 |
| Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation 2002 · group III · Haemodialysis patients with chronic renal failure and hyperhomocysteinaemia | 15 mg | — | 3 weeks | 7 |
| Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial 1997 · folic acid plus vitamin B12 · Clinically stable renal transplant recipients | 5 mg | 400 mcg | — | 7 |
| Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial 1997 · vitamin B6, folic acid, and vitamin B12 · Clinically stable renal transplant recipients | 5 mg | 400 mcg | — | 7 |
| Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients 2001 · Hemodialysis patients receiving folic acid · Hemodialysis patients with hyperhomocysteinemia and baseline total homocysteine comparable to the renal transplant recipients | 15 mg | 1 mg | 12 weeks | — |
| Oral vitamin B(12) and high-dose folic acid in hemodialysis patients with hyper-homocyst(e)inemia 2001 · 0 mg folic acid group · Adults with hyper-homocyst(e)inemia receiving hemodialysis for end-stage renal disease | 1 mg | 1 mg | 4 weeks | — |
| Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate 2001 · fenofibrate plus vitamins · men with hyperlipidemia | 650 mcg | 50 mcg | 6 weeks | — |
| Total homocysteine lowering treatment among coronary artery disease patients in the era of folic acid-fortified cereal grain flour 2002 · Folic acid, riboflavin, and vitamin B12 without vitamin B6 · Adults with stable coronary artery disease; mean age 60.1 years; 29.8% women | 2.5 mg | 400 mcg | 12 weeks | — |
| Hyperhomocysteinaemia therapy in haemodialysis patients: folinic versus folic acid in combination with vitamin B6 and B12 2002 · Group 3 · Chronic haemodialysis patients; age and sex not specified | 6.43 mg | 429 mcg | 26 weeks | — |
| Randomized trial of methylcobalamin and folate effects on homocysteine in hemodialysis patients 2002 · Group A · Chronic hemodialysis patients without previous vitamin supplementation | 10 mg | — | 120 days | — |
| Effect of homocysteine reduction by B-vitamin supplementation on markers of clotting activation 2002 · high-dose B-vitamin supplements · Healthy volunteers with homocysteine >16 μmol/L or ≤16 μmol/L | 5 mg | 400 mcg | 8 weeks | — |
| Coronary endothelial function in hyperhomocysteinemia: improvement after treatment with folic acid and cobalamin in patients with coronary artery disease 2002 · folic acid/cobalamin treated group · Patients with coronary artery disease and hyperhomocysteinemia, plasma homocysteine ≥16 micromol/L; age and sex not reported | 5 mg | 400 mcg | 26 weeks | — |
| Reduction of plasma homocysteine and serum methylmalonate concentrations in apparently healthy elderly subjects after treatment with folic acid, vitamin B12 and vitamin B6: a randomised trial 2003 · B-vitamin treatment · Community-dwelling apparently healthy adults aged 70–93 years; median age 76 years | 800 mcg | 500 mcg | 120 days | — |
| Mineral water fortified with folic acid, vitamins B6, B12, D and calcium improves folate status and decreases plasma homocysteine concentration in men and women 2004 · Fortified mineral water · Free-living men and women without folate deficiency or elevated homocysteine | 563 mcg | 7.5 mcg | 8 weeks | — |
| Breakfast cereal fortified with folic acid, vitamin B-6, and vitamin B-12 increases vitamin concentrations and reduces homocysteine concentrations: a randomized trial 2004 · Fortified cereal group · Volunteers aged 50–85 years without the listed medical conditions who did not regularly use multiple or B-vitamin supplements or highly fortified breakfast cereal | 440 mcg | 4.8 mcg | 12 weeks | — |
| Changes in basal and postmethionine load concentrations of total homocysteine and cystathionine after B vitamin intervention 2004 · group B · Patients with suspected coronary artery disease; age and sex not stated | 5.8 mg | 400 mcg | 90 days | — |
| Insulin resistance and endothelial function are improved after folate and vitamin B12 therapy in patients with metabolic syndrome: relationship between homocysteine levels and hyperinsulinemia 2004 · group 2 · Patients with metabolic syndrome; age range and sex not reported | 5 mg | 500 mcg | 30 days | — |
| The effect of homocysteine reduction by B-vitamin supplementation on markers of endothelial dysfunction 2004 · B-vitamins · Healthy volunteers, including hyperhomocysteinemic and normohomocysteinemic participants | 5 mg | 400 mcg | 8 weeks | — |
| Efficacy of B vitamins in lowering homocysteine in older men: maximal effects for those with B12 deficiency and hyperhomocysteinemia 2006 · Vitamin group · Community-dwelling men aged 75 years or older | 2 mg | 400 mcg | 2 years | — |
| Effect of short-term folate and vitamin B supplementation on blood homocysteine level and carotid artery wall thickness in chronic hemodialysis patients 2006 · Treatment group · Chronic hemodialysis patients with hyperhomocysteinemia; age and sex not specified | 15 mg | 1 mg | 26 weeks | — |
| Effect of fortified spread on homocysteine concentration in apparently healthy volunteers 2007 · spread 1 · Apparently healthy adult volunteers; 50% male; age range not reported | 200 mcg | 2 mcg | 6 weeks | — |
| Effect of fortified spread on homocysteine concentration in apparently healthy volunteers 2007 · spread 2 · Apparently healthy adult volunteers; 50% male; age range not reported | 400 mcg | 2 mcg | 6 weeks | — |
| Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease 2007 · A: folic acid/vitamin B12/vitamin B6 · Adults aged 38–80 with suspected coronary artery disease | 800 mcg | 400 mcg | 26 weeks | — |
| Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease 2007 · B: folic acid/vitamin B12 · Adults aged 38–80 with suspected coronary artery disease | 800 mcg | 400 mcg | 26 weeks | — |
| Folic acid and vitamin B-12 supplementation does not favorably influence uracil incorporation and promoter methylation in rectal mucosa DNA of subjects with previous colorectal adenomas 2007 · folic acid plus vitamin B-12 · People with a history of colorectal adenoma and MTHFR CC or TT genotype | 5 mg | 1.25 mg | 26 weeks | — |
| Treatment of hyperhomocysteinemia and endothelial dysfunction in renal transplant recipients with B vitamins in the Chinese population 2008 · folate treatment · Chinese renal transplant recipients with hyperhomocysteinemia; age and sex not reported | 5 mg | 1 mg | 26 weeks | — |
| Effect of homocysteine-lowering therapy on arterial elasticity and metabolic parameters in metformin-treated diabetic patients 2008 · group 1 · Adults with diabetes treated with high-dose metformin | 1 mg | 400 mcg | 120 days | — |
| Serum biomarkers for atrophic gastritis and antibodies against Helicobacter pylori in the elderly: Implications for vitamin B12, folic acid and iron status and response to oral vitamin therapy 2008 · oral vitamin treatment · Community-dwelling adults, mean age 76 years | 800 mcg | 500 mcg | 120 days | — |
| Weekly may be as efficacious as daily folic acid supplementation in improving folate status and lowering serum homocysteine concentrations in Guatemalan women 2008 · weekly 5000 microg folic acid group · Healthy reproductive-aged women in Guatemala | 714 mcg | — | 12 weeks | — |
| Weekly may be as efficacious as daily folic acid supplementation in improving folate status and lowering serum homocysteine concentrations in Guatemalan women 2008 · weekly 2800 microg folic acid group · Healthy reproductive-aged women in Guatemala | 400 mcg | — | 12 weeks | — |
| Weekly may be as efficacious as daily folic acid supplementation in improving folate status and lowering serum homocysteine concentrations in Guatemalan women 2008 · daily 400 microg folic acid group · Healthy reproductive-aged women in Guatemala | 400 mcg | — | 12 weeks | — |
| Weekly may be as efficacious as daily folic acid supplementation in improving folate status and lowering serum homocysteine concentrations in Guatemalan women 2008 · daily 200 microg folic acid group · Healthy reproductive-aged women in Guatemala | 200 mcg | — | 12 weeks | — |
| The effects of vitamin supplementation and MTHFR (C677T) genotype on homocysteine-lowering and migraine disability 2009 · vitamin supplementation · patients diagnosed with migraine with aura; age and sex not reported | 2 mg | 400 mcg | 26 weeks | — |
| Efficacy of folate and vitamin B12 in lowering homocysteine concentrations in hemodialysis patients 2009 · group II (folic acid and vitamin B12) · Hemodialysis patients; age and sex not reported | 5 mg | 1 mg | 8 weeks | — |
| Efficacy of folate and vitamin B12 in lowering homocysteine concentrations in hemodialysis patients 2009 · group IV (folic acid and vitamin B12) · Hemodialysis patients; age and sex not reported | 15 mg | 1 mg | 8 weeks | — |
| Homocysteine-lowering vitamins do not lower plasma S-adenosylhomocysteine in older people with elevated homocysteine concentrations 2010 · vitamins group · Healthy adults aged 65 years or older with elevated homocysteine (>13 micromol/l) | 1 mg | 500 mcg | 2 years | — |
| Effect of physiological doses of oral vitamin B12 on plasma homocysteine: a randomized, placebo-controlled, double-blind trial in India 2010 · B2 F200 (2 μg vitamin B12 and 200 μg folic acid) · Children and adults from rural families in India; participants included children (mean age 9 years), mothers and fathers, with common vitamin B12 deficiency and elevated homocysteine | 200 mcg | 2 mcg | 1 year | — |
| Effect of physiological doses of oral vitamin B12 on plasma homocysteine: a randomized, placebo-controlled, double-blind trial in India 2010 · B10 F200 (10 μg vitamin B12 and 200 μg folic acid) · Children and adults from rural families in India; participants included children (mean age 9 years), mothers and fathers, with common vitamin B12 deficiency and elevated homocysteine | 200 mcg | 10 mcg | 1 year | — |
| Community-level micronutrient fortification of school lunch meals improved vitamin A, folate, and iron status of schoolchildren in Himalayan villages of India 2010 · multiple micronutrients (treatment group) · Schoolchildren aged 6–10 years in Himalayan villages of India | 225 mcg | 1.35 mcg | 240 days | — |
| Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment 2013 · B-vitamin treatment · Elderly adults with mild cognitive impairment and increased dementia risk | 800 mcg | 500 mcg | 2 years | — |
| The association between progression of atherosclerosis and the methylated amino acids asymmetric dimethylarginine and trimethyllysine 2013 · Folic acid plus vitamin B12 plus vitamin B6 · Adults with suspected or established coronary artery disease who underwent coronary angiography; median age 60 years | 800 mcg | 400 mcg | 316 days | — |
| The association between progression of atherosclerosis and the methylated amino acids asymmetric dimethylarginine and trimethyllysine 2013 · Folic acid plus vitamin B12 · Adults with suspected or established coronary artery disease who underwent coronary angiography; median age 60 years | 800 mcg | 400 mcg | 316 days | — |
| The C677T MTHFR genotypes influence the efficacy of B9 and B12 vitamins supplementation to lowering plasma total homocysteine in hemodialysis 2016 · Group A, t3: folic acid plus vitamin B12 · Hemodialysis patients with C677T MTHFR genotypes | 10 mg | — | 60 days | — |
| The C677T MTHFR genotypes influence the efficacy of B9 and B12 vitamins supplementation to lowering plasma total homocysteine in hemodialysis 2016 · Group B, t3: vitamin B12 plus folic acid · Hemodialysis patients with C677T MTHFR genotypes | 10 mg | — | 60 days | — |
| Urinary excretion of homocysteine thiolactone and the risk of acute myocardial infarction in coronary artery disease patients: the WENBIT trial 2019 · folic acid + vitamin B12 + vitamin B6 · Adults with suspected coronary artery disease who underwent coronary angiography; mean age about 61 years, 69.8% male | 800 mcg | 400 mcg | 165 weeks | — |
| Urinary excretion of homocysteine thiolactone and the risk of acute myocardial infarction in coronary artery disease patients: the WENBIT trial 2019 · folic acid + vitamin B12 · Adults with suspected coronary artery disease who underwent coronary angiography; mean age about 61 years, 69.8% male | 800 mcg | 400 mcg | 165 weeks | — |
| Impact of daily-supervised administration of a package of iron and folic acid and vitamin B(12) on hemoglobin levels among adolescent girls (12-19 years): a cluster randomized control trial 2021 · Experimental group-IFA with vitamin B12 · Adolescent girls aged 12–19 years with mild or moderate anemia | 500 mcg | 1 mg | 90 days | — |
| Vitamin requirements for the treatment of hyperhomocysteinemia in humans 1994 · combination of folic acid, vitamin B-12 and vitamin B-6 · men with hyperhomocysteinemia | 650 mcg | 400 mcg | 6 weeks | — |
| Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia 1993 · daily vitamin supplement · Apparently healthy men with moderate hyperhomocysteinemia | 1 mg | 400 mcg | 6 weeks | — |
| Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers 1998 · high-dose multivitamin supplements · Patients with a history of recurrent venous thrombosis and hyperhomocysteinemic healthy volunteers | 5 mg | 400 mcg | — | — |
| Effects of folic acid and combinations of folic acid and vitamin B-12 on plasma homocysteine concentrations in healthy, young women 1998 · 400 microg folic acid + 6 microg vitamin B-12 · Female volunteers of childbearing age | 400 mcg | 6 mcg | 4 weeks | — |
| Effects of folic acid and combinations of folic acid and vitamin B-12 on plasma homocysteine concentrations in healthy, young women 1998 · 400 microg folic acid + 400 microg vitamin B-12 · Female volunteers of childbearing age | 400 mcg | 400 mcg | 4 weeks | — |
| Effects of prenatal micronutrient and early food supplementation on metabolic status of the offspring at 4.5 years of age. The MINIMat randomized trial in rural Bangladesh 2016 · MMS · Pregnant women in rural Bangladesh; offspring assessed at 4.5 years | 400 mcg | 2.6 mcg | — | 439 |
| Maternal cortisol and stress are associated with birth outcomes, but are not affected by lipid-based nutrient supplements during pregnancy: an analysis of data from a randomized controlled trial in rural Malawi 2015 · LNS · Pregnant women aged 15–49 years in rural Malawi, enrolled at up to 20 weeks of gestation | 400 mcg | 5.2 mcg | — | 418 |
| Maternal cortisol and stress are associated with birth outcomes, but are not affected by lipid-based nutrient supplements during pregnancy: an analysis of data from a randomized controlled trial in rural Malawi 2015 · MMN · Pregnant women aged 15–49 years in rural Malawi, enrolled at up to 20 weeks of gestation | 400 mcg | 5.2 mcg | — | 415 |
| A novel nutritional supplement to reduce plasma homocysteine in nonpregnant women: A randomised controlled trial in The Gambia 2019 · UNIMMAP tablet · Nonpregnant, non-lactating healthy women aged 18–45 years in West Kiang, The Gambia; women of reproductive age with common micronutrient deficiencies in the population | 400 mcg | 2.6 mcg | 12 weeks | 105 |
| A novel nutritional supplement to reduce plasma homocysteine in nonpregnant women: A randomised controlled trial in The Gambia 2019 · drink powder · Nonpregnant, non-lactating healthy women aged 18–45 years in West Kiang, The Gambia; women of reproductive age with common micronutrient deficiencies in the population | 800 mcg | 5.2 mcg | 12 weeks | 93 |
| Nutraceutical approaches to homocysteine lowering in hypertensive subjects at low cardiovascular risk: a multicenter, randomized clinical trial 2016 · Normocis 400® group · Adults with stage 1 essential hypertension and hyper-homocysteinemia (HCys ≥15 μmol/L), without a history of cardiovascular or cerebrovascular disease; mean age 62.8 years, 63.5% male | 400 mcg | 5 mcg | 60 days | 52 |
| Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD 2009 · Treatment group · Adults with stage 2 to 4 chronic kidney disease and creatinine clearance of 15 to 70 mL/min/1.73 m² | 5 mg | 1 mg | 2 years | 47 |
| Effects of low-dose B vitamins plus betaine supplementation on lowering homocysteine concentrations among Chinese adults with hyperhomocysteinemia: a randomized, double-blind, controlled preliminary clinical trial 2023 · supplement group · Chinese adults aged 18–65 with hyperhomocysteinemia (blood homocysteine 15–100 μmol/L) | 400 mcg | 6.4 mcg | 12 weeks | 44 |
| Plasma trimethylamine-N-oxide following supplementation with vitamin D or D plus B vitamins 2017 · vitamin D + B arm · Participants; age, sex, and health condition not specified | 500 mcg | 500 mcg | 1 year | 25 |
| High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients 1996 · Supraphysiologic-dose B-vitamin supplementation · Hyperhomocysteinemic dialysis patients | 15 mg | 1 mg | 8 weeks | 15 |
| Folic acid 5 or 15 mg/d similarly reduces plasma homocysteine in patients with moderate-advanced chronic renal failure 2006 · FA-15 · Adults aged 45–71 years with moderate-severe chronic renal failure | 15 mg | — | 180 days | 9 |
| Folic acid 5 or 15 mg/d similarly reduces plasma homocysteine in patients with moderate-advanced chronic renal failure 2006 · FA-5 · Adults aged 45–71 years with moderate-severe chronic renal failure | 5 mg | — | 180 days | 8 |
| Oral vitamin B(12) and high-dose folic acid in hemodialysis patients with hyper-homocyst(e)inemia 2001 · 5 mg folic acid group · Adults with hyper-homocyst(e)inemia receiving hemodialysis for end-stage renal disease | 6 mg | 1 mg | 4 weeks | — |
| Oral vitamin B(12) and high-dose folic acid in hemodialysis patients with hyper-homocyst(e)inemia 2001 · 20 mg folic acid group · Adults with hyper-homocyst(e)inemia receiving hemodialysis for end-stage renal disease | 21 mg | 1 mg | 4 weeks | — |
| Prophylactic iron supplementation in pregnant women in Norway 2001 · 15 mg iron daily · Non-anaemic pregnant women, allocated at about 10 weeks of pregnancy | 100 mcg | 3 mcg | — | — |
| Total homocysteine lowering treatment among coronary artery disease patients in the era of folic acid-fortified cereal grain flour 2002 · Folic acid, riboflavin, and vitamin B12 with vitamin B6 · Adults with stable coronary artery disease; mean age 60.1 years; 29.8% women | 2.5 mg | 400 mcg | 12 weeks | — |
| Folate therapy and in-stent restenosis after coronary stenting 2004 · folate group · Patients who had undergone successful coronary stenting | 1.2 mg | 60 mcg | 26 weeks | — |
| Changes in basal and postmethionine load concentrations of total homocysteine and cystathionine after B vitamin intervention 2004 · group A · Patients with suspected coronary artery disease; age and sex not stated | 5.8 mg | 400 mcg | 90 days | — |
| Homocysteine in chronic kidney disease: Effect of low protein diet and repletion with B vitamins 2005 · All subjects · Adults with chronic kidney disease in MDRD Study A (GFR 25–55 mL/min/1.73 m²) or Study B (GFR 13–24 mL/min/1.73 m²) | 1 mg | 6 mcg | 1 year | — |
| No effect of homocysteine-lowering therapy on vascular inflammation and haemostasis in peripheral arterial occlusive disease 2006 · B-vitamin group · Patients with symptomatic peripheral arterial occlusive disease and elevated homocysteine levels | 5 mg | 50 mcg | 6 weeks | — |
| One year B and D vitamins supplementation improves metabolic bone markers 2013 · group A · Healthy adults older than 54 years | 500 mcg | 500 mcg | 1 year | — |
| Co-administration of methyl donors along with guanidinoacetic acid reduces the incidence of hyperhomocysteinaemia compared with guanidinoacetic acid administration alone 2013 · GAA with methyl donors group · Healthy male and female volunteers | 600 mcg | 5 mcg | 8 weeks | — |
| Effects of mixed dietary supplements on total plasma homocysteine concentrations (tHcy): a randomized, double-blind, placebo-controlled trial 2012 · supplement group · hospitalized, acutely ill older patients recovering from acute illness; sex and age range not stated | 200 mcg | 1.5 mcg | 6 weeks | — |
| One-carbon metabolites and telomere length in a prospective and randomized study of B- and/or D-vitamin supplementation 2017 · group A · Adults older than 54 years; no specific condition stated | 500 mcg | 500 mcg | 1 year | — |
| Multimicronutrient and omega-3 fatty acid supplementation reduces low-grade inflammation in older participants: An exploratory study 2025 · multimicronutrient and n-3 PUFA supplementation · Healthy, physically active older adults; mean age 75.6 ± 3.9 years; sex not specified | 400 mcg | 100 mcg | 12 weeks | — |
| Vitamin B12 Supplementation in Addition to Folic Acid and Iron Improves Hematological and Biochemical Markers in Pregnancy: A Randomized Controlled Trial 2020 · intervention group · Healthy, nonanemic pregnant women; age and sex details beyond pregnancy not reported | 5 mg | 5 mcg | 100 days | — |
| Betaine as a determinant of postmethionine load total plasma homocysteine before and after B-vitamin supplementation 2004 · folic acid, vitamin B12, and vitamin B6 group · Patients undergoing coronary angiography | 800 mcg | 400 mcg | 1 year | — |
| Betaine as a determinant of postmethionine load total plasma homocysteine before and after B-vitamin supplementation 2004 · folic acid and vitamin B12 group · Patients undergoing coronary angiography | 800 mcg | 400 mcg | 1 year | — |